Recent 8-K filings for TTRX

Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.

• May 11, 2026 20:10 UTC earnings item 2.02item 9.01

  Turn Therapeutics Q1 net loss $971K; Phase 2 AD trial on track, topline mid-2026

source · TTRX on sec.gov